Strategic Alliances Leverage Augmenta’s history of joint development with TFF Pharmaceuticals and Catalent Biologics to propose co-development or licensing discussions around augmenting existing monoclonal antibody programs with their human-derived mAbs for COVID-19 therapeutics or related immune-modulation targets.

Immune Profiling Position offerings around Augmenta’s immune profiling capability to identify protective immune responses in patient cohorts, enabling target discovery partnerships, companion diagnostics development, or precision medicine collaborations for infectious disease and oncology programs.

Clinical Manufacturing Offer scalable manufacturing collaborations by aligning with the company’s prior engagement with contract manufacturers, emphasizing early-phase to late-phase cell line development and drug substance manufacturing support to accelerate programs leveraging their mAb platform.

Biotech Partner Fit Target mid-sized biotech firms focused on infectious diseases, immunology, or biologics who need innovative antibody platforms and immune-based therapy pipelines, highlighting the potential for joint development, licensing, or strategic partnerships with Augmenta.

Funding & Traction Highlight their revenue scale and recent collaboration history to reassure potential partners of credibility and market traction, and explore opportunities to co-fund joint projects, equity collaborations, or milestone-based deals tied to clinical progress.